Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving nucleic acid
Reexamination Certificate
2005-09-13
2005-09-13
Nguyen, Dave T. (Department: 1635)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving nucleic acid
C435S091100, C536S022100, C536S023100
Reexamination Certificate
active
06942967
ABSTRACT:
The invention concerns the use of the apobec-1 protein or associated proteins for treating atherosclerosis and obesity, type II diabetes (non-insulin-dependent), or other diseases, characterised in particular by hyperlipidemia and/or hyperglycemia, caused for example by a level of chylomicrons and/or VLDL in the plasma above normal. The invention also concerns the cloning of the gene(s) of Anderson disease as target for treating atheroscelerosis, obesity and type II diabetes (non-insulin-dependent), or other diseases characterised in particular by hyperlipidemia and/or hyperglycermia.
REFERENCES:
patent: 6210888 (2001-04-01), Harosh
patent: 2 762 014 (1998-10-01), None
patent: WO 98/45472 (1998-10-01), None
Kenney et al. Blood 92(5):1721-127; 1998 “Antisense to the epstein-barr virus (EBV)-encoded latent membrane protein 1 (LMP-1) suppresses LMP-1 and bcl-2 expression and promotes apoptosis in EBV-immortalized B cells.”
Teng et al. Secience 1993 (260):1816-1819 “Molecular cloning of an ApolipoproteinB messenger RNA editing protein”.
Farnier M. et al. Current and future treatment of hyperlipidemia: the role of statins. American Journal of Cardiology, vol. 82, No. 4B, pp. 3J-10J; 1998.
Knowles et al. Genetic modifiers of atheroslerosis in mice. Artioscler. Thromb. Vasc. Biol., vol. 20, No. 11, pp. 2336-2345; 2000.
van Tilburg J. et al. Defining the genetic contribution of type 2 diabetes mellitus. Journal of Medical Genetics, vol. 38, No. 9, pp. 569-578; 2001.
Braasch, D. et al. Biochemistry 2002; vol. 41, No. 14, pp. 4503-4510.
Branch, A. Trends in Biochemistry 1998; vol. 23, pp. 45-50.
Gewirtz, A. et al. Proc. Natl. Acad. Sci., U.S.A. 1996; vol. 93, pp. 3161-3163.
Agrawal, S. Trends in Biotechnology 1996, vol. 14, pp. 376-387.
Tamm, I. et al. The Lancet 2001, vol. 358, pp. 489-497.
Bostrom. K., “Apolipoprotein B m RNA Editing”.The Journal of Biological Chemistry. vol. 265, No. 36, pp. 22446-22452 (1990).
Patel S., “Chylomicron retention disease: exclusion of apolipoprotein B gene defects and detection of mRNA editing in an affected family”.Atherosclerosis. vol. 108, pp. 201-207 (1994).
GenBank Accession No. D90151, May 25, 1990.
GenBank Accession No. L26234, Jan. 4, 1995.
GenBank Accession No. U76713, Oct. 30, 1996).
GenBank Accession No. U22264, Mar. 6, 1995.
GenBank Accession No. L07114, Apr. 4, 1994.
GenBank Accession No. U10695, Jun. 14, 1994.
Lau, et al.; “Cloning of an Apobec-1-binding Protein That Also Interacts with Apolopoprotein B mRNA and Evidence for Its Involvement in RNA Editing”;Journal of biological Chemistry; Jan. 17, 1997; vol. 272, No. 3, pp. 1452-1455.
Phung, et al.: “Regulation of Hepatic Apolipoprotein B RNA Editing in the Genetically Obese Zucker Rat”;Metabolism; Sep. 1996; vol. 45, pp. 1056-1058.
Oka, et al.: “Tissue-specific Inhibition of Apolipoprotein B mRNA Editing in the Liver by Adenovirus-mediated Transfer of a Dominant Negative Mutant APOBEC-1 Leads to Increased Low Density Lipoprotein in Mice”;Journal of Biological Chemistry; Jan. 17, 1997; vol. 272, pp. 1456-1460.
Anant, et al, “AU-rich RNA Binding proteins Hel-N1 and AUF1 bind apolipoprotein B mRNA and inhibit posttranscriptional C to U editing”;Nucleic Acids Symposium Series; 1997; vol. 36, pp. 115-118.
Greeve, et al.: “Reconstitution of apoB mRNA editing in liver by gene-transfer as a potential approach for the treatment of severe forms of polygenic hypercholesterolemia-an outline of the rationale”;Zeitschrift Fuer Gastroenterologie; Jun. 1996; vol. 34, No. Suppl. 03, pp. 27-30.
Smith, et al.: “Base-modificaton mRNA editing through deamination—the good, the bad and the unregulated”;Trends in Genetics; Oct. 1996; vol. 12, No. 10, pp. 418424.
Chan I. (1995) “Apolipoprotein B messenger RNA editing; An update”Biochimie. pp. 75-78.
Teng B et al. (1993) “Molecular cloning of an Apolipoprotein B Messenger RNA Editing Protein” Science, vol. 260, pp. 1816-1819.
Lau PP (1994) “Dimeric structure of a human apolipoprotein B mRNA editing protein and cloning and chromosomal localization of its gene” Proc. Natl. Acad. Sci. USA. vol. 91, pp. 8522-8526.
Giannoni et al (1994) “Complementation of Apolipoprotein B mRNA Editing by Human Liver Accompanied by Secretion of Apolipoprotein B48” J. Biol. Chem., vol. 269, No. 8, pp. 5932-5936.
Hirano K et al. (1996) “Targeted Disruption of the mouse apobec-I Gene Abolishes Apolipoprotein B mRNA Editing and Eliminates Apolipoprotein B48” A. Biol. Chem., vol. 271, pp. 9887-9890.
Morrison JR et al (1996) “Apolipoprotein B RNA editing enzyme deficient mice are viable despite alterations in lipoprotein metabolism,” Proc. Natl. Acad. Sci. USA, vol. 93, pp. 7154-7159.
Havel RJ and Kane JP (1995) “The metabolic and molecular basis of inherited disease”, Chapter 56 and Chapter 57. pp 1841-1885.
Sharp D et al. (1993) “Cloning and gene defects in microsomal triglyceride transfer protein associated with abetalipoproteinaemia” Nature, vol. 365, pp. 65-69.
Wetterau JR et at. (1992) “Absence of Microsomal Triglyceride Transfer Protein in Individuals with Abetalipoproteinemia” Science, vol. 258, pp. 999-1001.
Linton MF et al. (1993) “Familial hypobetalipoproteinemia” J Lipid res., vol. 34, pp. 521-541.
Rosseneu M and Lauber CL (1995)“Physological significance of apolipoprotein mutants” FASEB J., pp. 768-776.
Anderson CM et al. (1961) “Unusual Causes of steatorrhoea in infancy and childhood”. Med. J. Aust., pp. 617-622.
Pessah M et al. (1991) “Anderson's Disease: Genetic Exclusion of the Apolipoprotein-B Gene in Two Families” J. din. Invest., vol. 87, pp. 367-370.
Strich D et al. (1993) “Anderson's Disease: No linkage to the apo B Locus” J. Pediatric Gastro. Nutrit., vol. 16, No. 3, pp. 257-264.
Levy E et al. (1987) “Intestinal apoB synthesis, lipids, and lipoproteins in chylomicron retention disease” J. Lipid Res., vol. 28, pp. 1263-1274.
Shah RR et al. (1991) “Sequence Requirements for the Editing of Apolipoprotein B mRNA” J. Biol. Chem., vol. 266, No. 25, pp. 16301-16304.
Kaneko-Ishino T et al., (1995) “Peg1/Mest imprinted gene on chromosome 6 identified by cDNA subtraction hybridization”, Nature Genet., vol. 11, pp 52-59.
Davies MS et al (1989) “Sequence Requirements for Apolipoprotein B RNA Editing in Transfected Rat Hepatoma Cells”. J Biol Chem. vol. 264, No. 23, pp. 13395-13398.
Uhlmann P and Peyman A (1990)“Antisense Oligonucleotides A New Therapeutic Principle” Chem Rev. vol. 90, No. 4, pp. 543-584.
Bostrom, K., “Apolipoprotein B m RNA Editing”,The Journal of Biological Chemistry, vol. 265, no. 36, pp. 22446-22452 (1990).
Patel, S., “Chylomicron retention disease: exclusion of apolipoprotein B gene defects and detection of mRNA editing in an affected family”,Atherosclerosis, vol. 108, pp. 201-207 (1994).
Barroso et al., “Dominant negative mutations in human PPARγ associated with severe insulin resistance, diabetes mellitus and hypertension”,Nature, 402:880-883 (Dec. 1999).
Harris et al., “RNA Editing Enzyme APOBEC1 and Some of its Homologs can Act as DNA Mutators”,Mol. Cell, 10:1247-1253 (Nov. 2002).
Kendrick et al., “Superior role of apolipoprotein B48 over apolipoprotein B100 in chylomicron assembly and fat absorption: an investigation of apobec-1 knock-out and wild-type mice”,Biochem. J., 356:821-827 (2001).
Larsen et al., “PPARgamma agonists in the treatment of type II diabetes: is increased fatness commensurate with long-term efficacy”, International Journal of Obesity, 27:147-161 (2003).
Taboit-Damcron et al., “Association of the 5'HS4 sequence of the chicken β-globin locus control region with human EF1αgene promoter induces ubiquitous and high expression o
Angell Jon Eric
Merchant & Gould P.C.
Nguyen Dave T.
Obe Therapy Biotechnology
LandOfFree
Target for treating athersclerosis, obesity and type II... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Target for treating athersclerosis, obesity and type II..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Target for treating athersclerosis, obesity and type II... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3438996